医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Delta-Fly Pharma, Inc. Initiated Phase 3 Clinical Study of DFP-10917 and Phase 1 Clinical Study of DFP-14927

2019年11月26日 PM06:13
このエントリーをはてなブックマークに追加


 

TOKUSHIMA, Japan

Delta-Fly Pharma, Inc. (TOKYO: 4598) announces that patients have registered for clinical studies in the USA on anti-cancer drug candidates DFP-10917 and DFP-14927.

DFP-10917 is an anti-cancer agent in development for the treatment of patients with Refractory/Relapsed Acute Myelogenous Leukemia. A Phase 3 clinical study at MD Anderson Cancer Center in Texas, USA and other sites in the USA is underway.

Two patients at UT Southwestern Medical Center in Texas and Banner MD Anderson Cancer Center in Arizona registered for this study in November 2019.

In addition, a Phase 1 clinical study of DFP-14927, the polymeric delivery of DFP-10917 in patients with advanced solid tumors has been initiated at MD Anderson Cancer Center.

Two patients registered for this study in October of this year and treatment is ongoing.

Company’s profile

Company name

     

Delta-Fly Pharma, Inc. [TOKYO:4598]

Capital

     

2849 million Japanese Yen

Name and Title of Representative

     

Kiyoshi Eshima, PhD, President

Date of Incorporation

     

December 6, 2010

Description of Business

     

Research and development, manufacturing and marketing of pharmaceuticals

Head Office

     

37-5, Nishikino, Miyajima, Kawauchi-cho, Tokushima 771-0116, Japan

Branch Office

     

Tokyo, Beijing, Vancouver

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005329/en/

CONTACT

Delta-Fly Pharma, Inc.

Inquiries: Yasuo Matsueda 

TEL: +81-(0)3-6231-1278

ymatsueda1206@delta-flypharma.co.jp

https://www.delta-flypharma.co.jp/

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China
  • OliX Announces Completion of USD 45 Million Capital Raise for R&D and Financial Structure Improvement
  • FEELM Wins 4 Red Dot Awards for Product Design 2022 for Innovative Atomization Products
  • Genexine Appoints Industry Veteran Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation
  • Genexine to Present at H.C. Wainwright Global Investment Conference